Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Sees Significant Growth in Short Interest

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) was the recipient of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 145,500 shares, an increase of 63.3% from the October 31st total of 89,100 shares. Approximately 2.7% of the company’s shares are short sold. Based on an average daily volume of 340,600 shares, the days-to-cover ratio is currently 0.4 days.

Protagenic Therapeutics Price Performance

Shares of Protagenic Therapeutics stock traded down $0.01 on Friday, hitting $0.59. The company had a trading volume of 115,991 shares, compared to its average volume of 364,659. The stock has a 50-day moving average of $0.62 and a 200-day moving average of $0.79. The firm has a market capitalization of $4.01 million, a P/E ratio of -0.46 and a beta of 0.24. Protagenic Therapeutics has a twelve month low of $0.49 and a twelve month high of $1.87.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.